Peter Humphrey, MD, PhD, Talks Multidisciplinary Aspects of Oncology Research

Video

At the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, Peter Humphrey, MD, PhD, spoke about how the conference catered to the multidisciplinary audience, and what he learned from that.

CancerNetwork® spoke with Peter Humphrey, MD, PhD, professor of pathology and director of Genitourinary Pathology at Yale School of Medicine in New Haven, Connecticut, about how he felt the multidisciplinary nature of the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, hosted by Physicians’ Education Resource®, LLC (PER®) was useful for future practice. Humphrey also talked about utilizing tumor boards where clinicians from different departments can discuss current topics.

Transcript:

One of the reasons I so enjoy this conference is the multidisciplinary nature. There’s directional learning and I’ve learned so much from my clinical colleagues today about their management based upon our diagnosis, for example. I think the same is true for when we present our diagnostic approach and how that diagnosis would influence them and their patient management. That multidisciplinary nature [for] taking care of patients with cancer, any cancer, is so vital.

I also appreciate that locally at Yale where we have weekly tumor boards, we have interactions amongst all of us including medical oncologists, urologist, interventional radiologists, diagnostic radiologists, and pathologists. Only by all of all of us having an input can we get a complete picture of the patient’s status at that point in time and have a vibrant discussion about treatment options. Depending upon the diagnosis and what radiologists and pathologists see at that point in time and in the patient’s care, it’s [providing] ongoing medical education for everyone while at the same time being practical in care of the patient.

Recent Videos
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Despite CD19 CAR T-cell therapy exhibiting efficacy in patients with relapsed/refractory large B-cell lymphoma, less than half achieve long-term remission.
Current findings from the phase 1/2 CaDAnCe-101 trial show no predictive factors of improved responses with BGB-16673 in patients with CLL or SLL.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
Related Content